The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension

EC Derrett-Smith, CP Denton(The Royal Free Hospital), K. J. CLARK, Irena Konstantinova, Pierre Broqua(Inventiva (France)), Shi-fang Xu, Junien Jl, Dietmar Abraham(Medical University of Vienna), Olivier Lacombe

UCL Discovery (University College London)

November 11, 2019

Cited by 0

Related Papers

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

|Annals of the Rheumatic Diseases|2003|769

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

|Annals of the Rheumatic Diseases|2010|503

Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation

|Journal of Biological Chemistry|2000|219

Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

|Journal of Hepatology|2020|163

Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate

|European Neurology|2008|99